Caffeine in Parkinson disease: Better for cruise control than snooze patrol?

Neurology

Volumn 79, Issue 7, 2012, Pages 616-618

  Schwarzschild, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; CAFFEINE; DOPAMINE 2 RECEPTOR; ISTRADEFYLLINE; LEVODOPA; PLACEBO; PRELADENANT; TOZADENANT;

BRADYKINESIA; DAYTIME SOMNOLENCE; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERANCE; DYSKINESIA; EDITORIAL; HUMAN; INSOMNIA; LONG TERM CARE; LOW DRUG DOSE; MOTOR PERFORMANCE; MUSCLE RIGIDITY; NERVE DEGENERATION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

EID: 84866091708     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318263580e     Document Type: Editorial

References (10)

1. Fuxe K, Ungerstedt U. Action of caffeine and theophyllamine on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists. Med Biol 1974; 52:48 -54.
2. Shoulson I, Chase T. Caffeine and the antiparkinsonian response to levodopa or piribedil. Neurology 1975;25: 722-724.
3. Kartzinel R, Shoulson I, Calne DB. Studies with bromocriptine: III: concomitant administration of caffeine to patients with idiopathic parkinsonism. Neurology 1976; 26:741-743.
4. Kitagawa M, Houzen H, Tashiro K. Effects of caffeine on the freezing of gait in Parkinson's disease. Mov Disord 2007;22:710 -712.
5. Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 2012;79:651- 658.
6. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999;51:83-133.
7. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 2006;29:647- 654.
8. Moresco RM, Todde S, Belloli S, et al. In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416. Eur J Nucl Med Mol Imaging 2005; 32:405- 413.
9. Yu L, Shen HY, Coelho JE, et al. Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol 2008;63: 338 -346.
10. Pinna A, Fenu S, Morelli M. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 2001;39:233-238.